Obesity
Conditions
Keywords
obesity, endocannabinoids
Brief summary
Up till now, the evaluation of the endocannabinoid system (ECS) in humans needs invasive procedures. The investigators managed in the lab to determine the levels of endocannabinoids in a small number of subjects. The aim of the study is to confirm that salivary is a useful tool to evaluate the activity of the ECS both in normal weight and obese subjects that are characterised by a hyperactivity of the system. Therefore, the first objective of the study is to compare the fasting level of salivary anandamide between 12 obese patients and 12 normal weight subjects.
Detailed description
The prevalence of obesity keeps increasing in industrialized countries. However, efficient treatments of this chronic disease are still lacking. A better understanding of the systems that regulate energy balance and eating behavior is mandatory to better understand the disease and find appropriate treatments. The endocannabinoid system (ECS) which comprises cannabinoid receptors, such as CB1 and CB2, endogenous ligands (named endocannabinoids) and specific biosynthetic and degradative pathways is a key system in the regulation of energy balance and obesity. Obesity is characterised by an hyperactivity of the system both in animal and humans. Moreover, the activity of the ECS is influenced by feeding status although only one study has only been performed in humans. The investigation of the ECS in humans needs invasive procedure (blood sampling or adipose or liver biopsy). The aim of our study is to evaluate a new tool for the ECS evaluation in humans i e the determinations of saliva concentration of endocannabinoids both in normal weight and obese subjects before and after food intake. Blood and saliva sampling will be performed after an overnight fast, one hour before, just before and one hour after a lunch in12 normal weight subjects and 12 obese characterised with anthropometric (Weight, height, BMI (Body Mass Index), waist circumference, blood pressure) and metabolic (glycaemia, insulin, lipid profile, liver profile) evaluations. The endocannabinoids concentrations will be measured with mass spectrometry in blood and saliva and gut hormones (PYY (peptide YY) and ghrelin) will be measured in plasma.
Interventions
BIOLOGICALBiological data
Height, Weight, waist circumference and systolic and diastolic blood pressure will be measured in obese and normal subjects. Blood and saliva sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch. This will allow a measurement of fasting glycaemia and insulin, fasting cholesterol and triglycerides, liver profile. Endocannabinoids will be measured both in plasma and saliva at each time point. Gut hormones (Ghrelin and PYY) will be measured before, just before and after lunch in plasma.
Sponsors
University Hospital, Bordeaux
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
Obese patients : * Age between 18 and 65 yrs * BMI (Body Mass Index) \> 30 kg/m² * Signed inform Consent before any investigation related to the study * No smoker Normal weight subjects : * Age between 18 and 65 yrs * BMI between 18 and 25 kg/m² * Signed inform Consent before any investigation related to the study * No smoker
Exclusion criteria
* treatments that could interfere with the endocannabinoid system (anxiolytics, anticonvulsivants, antidepressants drugs) * pregnancy, breast feeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Anandamide(AEA)concentration | Saliva sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch | The primary outcome will be the difference of fasting saliva anandamide (AEA) concentration between obese and normal weight subjects. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 2-AG( 2 arachidonoylglycerol), OEA (oleoylethanolamide), PEA (palmitoyléthanolamide) concentrations | Saliva sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch | to study fasting saliva concentration of 2-AG (2 arachidonoylglycerol), OEA (oleoylethanolamide), PEA(palmitoyléthanolamide) between obese and lean subjects |
| Food intake influence on saliva endocannabinoids | Saliva sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch | To study the effects of food intake on the levels of saliva endocannabinoids both in normal weight and obese subjects |
| Plasma endocannabinoids level | Blood sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch | To study the effects of food intake on the levels of plasma endocannabinoids both in normal weight and obese subjects |
| Correlation between saliva and plasma endocannabinoids | Blood and saliva sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch | To look for a correlation between saliva and plasma endocannabinoids |
| Relationship between saliva or plasma endocannabinoids and gut hormones | Blood and saliva sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch | To look for a relationship between saliva or plasma endocannabinoids and gut hormones |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORBlandine GATTA, Dr
University Hospital, Bordeaux
Outcome results
None listed